Machine Learning to Identify Predictors of Glycemic Control in Type 2 Diabetes: An Analysis of Target HbA1c Reduction Using Empagliflozin/Linagliptin Data

被引：0
|
作者：
Angelo Del Parigi
Wenbo Tang
Dacheng Liu
Christopher Lee
Richard Pratley
机构：
[1] Boehringer Ingelheim Pharmaceuticals Inc.,
[2] Boehringer Ingelheim GmbH & Co. KG,undefined
[3] Florida Hospital Diabetes Institute,undefined
[4] AdventHealth Translational Research Institute for Metabolism and Diabetes,undefined
来源：
Pharmaceutical Medicine | 2019年 / 33卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
What did this study look at?This study looked at whether a computer program could predict which people with type 2 diabetes would respond best to a particular treatment.The study treatment was a single-pill combination of two medicines, empagliflozin [em-PAH-gli-FLOW-zin] and linagliptin [LYNN-nah-GLIP-tin]. It is used to lower blood sugar (blood glucose) in people with type 2 diabetes.The researchers used machine learning to analyze data from people who received this treatment. Machine learning uses computer models to find patterns in information.The results helped to predict which people might respond best to the treatment.
引用
收藏
页码：209 / 217
页数：8
相关论文
共 50 条
  • [21] Relationship Between HbA1c on Target, Risk of Silent Hypoglycemia and Glycemic Variability in Patients with Type 2 Diabetes Mellitus
    Engler, B.
    Koehler, C.
    Hoffmann, C.
    Landgraf, W.
    Bilz, S.
    Schoner, C.
    Bornstein, S. R.
    Hanefeld, M.
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2011, 119 (01) : 59 - 61
  • [22] Poor glycemic control in type 2 diabetes in the South of the Sahara: The issue of limited access to an HbA1c test
    Camara, Alioune
    Balde, Naby M.
    Sobngwi-Tambekou, Joelle
    Kengne, Andre P.
    Diallo, Mansour M.
    Tchatchoua, Alain P. K.
    Kake, Amadou
    Sylvie, Ngamani
    Balkau, Beverley
    Bonnet, Fabrice
    Sobngwi, Eugene
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2015, 108 (01) : 187 - 192
  • [23] Change in HbA1c associated with treatment intensification among patients with type 2 diabetes and poor glycemic control
    Fu, Alex Z.
    Sheehan, John J.
    CURRENT MEDICAL RESEARCH AND OPINION, 2017, 33 (05) : 853 - 858
  • [24] Importance of using HbA1c data of total diabetes duration in studying the relation between HbA1c value and retinopathy in type 1 diabetes
    Hirose, A.
    Kitano, S.
    Uchigata, Y.
    DIABETOLOGIA, 2014, 57 : S27 - S27
  • [25] Impact of fasting and postprandial glycemia on overall glycemic control in type 2 diabetes -: Importance of postprandial glycemia to achieve target HbA1c levels
    Woerle, Hans J.
    Neumann, Christoph
    Zschau, Silvia
    Tenner, Stephanie
    Irsigler, Andrea
    Schirra, Joerg
    Gerich, John E.
    Goeke, Burkhard
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2007, 77 (02) : 280 - 285
  • [26] Eating Behaviors, Personality Traits, and Diabetes Fatalism: Predictors of HbA1c in Type 2 Diabetes
    Farran, Natali
    Sukkarieh-Haraty, Ola Ali
    Al Bakhour, Dalal
    Bassil, Maya
    DIABETES, 2019, 68
  • [27] Efficacy and safety of empagliflozin in younger overweight/obese patients with Type 2 diabetes with HbA1c ≥8%
    Merker, L.
    Lund, S. S.
    Hantel, S.
    Salsali, A.
    Kim, G.
    Broedl, U. C.
    Woerle, H. J.
    Hach, T.
    DIABETIC MEDICINE, 2015, 32 : 90 - 90
  • [28] One-year sustained glycemic control and weight reduction in type 2 diabetes after addition of liraglutide to metformin followed by insulin detemir according to HbA1c target
    Rosenstock, Julio
    Rodbard, Helena W.
    Bain, Stephen C.
    D'Alessio, David
    Seufert, Jochen
    Thomsen, Anne B.
    Svendsen, Claus Bo
    DeVries, J. Hans
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2013, 27 (05) : 492 - 500
  • [29] Influence of Glycemic Variability on the HbA1c Level in Elderly Male Patients with Type 2 Diabetes
    Fang, Fu-Sheng
    Li, Zhi-Bing
    Li, Chun-Lin
    Tian, Hui
    Li, Jian
    Cheng, Xiao-Ling
    INTERNAL MEDICINE, 2012, 51 (22) : 3109 - 3113
  • [30] Early Combination Therapy with Linagliptin and Metformin in People with Type 2 Diabetes Improves Glycemic Control to HbA1c ≤ 6.5% without Increasing Hypoglycemia: Pooled Analysis of Two Randomized Clinical Trials
    Qian Lv
    Jie Shen
    Lin Miao
    Binqi Ye
    Cornelia Schepers
    Arian Plat
    Yongquan Shi
    Diabetes Therapy, 2020, 11 : 1317 - 1330
12345